Astria Therapeutics, Inc.
Astria Therapeutics, Inc. (ATXS) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · ATXS · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
1
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Astria Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
ATXS insider buying and selling by quarter
ATXS insider selling · ATXS insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · ATXS ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
ATXS executive sell shares · ATXS board member insider trading · ATXS insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jan 23, 2026 | Violin Jonathan Director | Other | 263,321 | — | Form 4 |
| Jan 23, 2026 | Milne Jill C. CEO and President · Director | Other | 4,377 | — | Form 4 |
| Jan 23, 2026 | Komjathy Andrew Chief Commercial Officer | Other | 45 | — | Form 4 |
| Apr 1, 2024 | Morabito Christopher Chief Medical Officer | Option | 10,000 | $39K | Form 4 |
| Apr 1, 2024 | Morabito Christopher Chief Medical Officer | Sale | 10,000 | $136K | Form 4 |
| Feb 1, 2024 | PERCEPTIVE ADVISORS LLC Director | Purchase | 2,481,350 | $30.00M⚡ | Form 4 |
| Jan 29, 2024 | Morabito Christopher Chief Medical Officer | Option | 9,200 | $36K | Form 4 |
| Jan 26, 2024 | Morabito Christopher Chief Medical Officer | Option | 800 | $3K | Form 4 |
| Jan 29, 2024 | Morabito Christopher Chief Medical Officer | Sale | 9,200 | $103K | Form 4 |
| Jan 26, 2024 | Morabito Christopher Chief Medical Officer | Sale | 800 | $9K | Form 4 |
| Dec 21, 2023 | PERCEPTIVE ADVISORS LLC Director | Purchase | 740,000 | $4.59M⚡ | Form 4 |
| Oct 16, 2023 | PERCEPTIVE ADVISORS LLC Director | Purchase | 614,062 | $4.00M⚡ | Form 4 |
| Oct 16, 2023 | PERCEPTIVE ADVISORS LLC Director | Purchase | 460,546 | $3.00M⚡ | Form 4 |
Milne Jill C.
CEO and President · Director
Date
Jan 23
Shares
4,377
Price
—
Value
—
Morabito Christopher
Chief Medical Officer
Date
Apr 1
Shares
10,000
Price
$3.87
Value
$39K
Morabito Christopher
Chief Medical Officer
Date
Apr 1
Shares
10,000
Price
$13.59
Value
$136K
PERCEPTIVE ADVISORS LLC
Director
Date
Feb 1
Shares
2,481,350
Price
$12.09
Value
$30.00M ⚡
Morabito Christopher
Chief Medical Officer
Date
Jan 29
Shares
9,200
Price
$3.87
Value
$36K
Morabito Christopher
Chief Medical Officer
Date
Jan 26
Shares
800
Price
$3.87
Value
$3K
Morabito Christopher
Chief Medical Officer
Date
Jan 29
Shares
9,200
Price
$11.15
Value
$103K
Morabito Christopher
Chief Medical Officer
Date
Jan 26
Shares
800
Price
$11.02
Value
$9K
PERCEPTIVE ADVISORS LLC
Director
Date
Dec 21
Shares
740,000
Price
$6.20
Value
$4.59M ⚡
PERCEPTIVE ADVISORS LLC
Director
Date
Oct 16
Shares
614,062
Price
$6.51
Value
$4.00M ⚡
PERCEPTIVE ADVISORS LLC
Director
Date
Oct 16
Shares
460,546
Price
$6.51
Value
$3.00M ⚡
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About ATXS insider trading
ATXS insider trades
Astria Therapeutics, Inc. (ATXS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Violin Jonathan (Director), Milne Jill C. (CEO and President · Director), Komjathy Andrew (Chief Commercial Officer). Over the past 12 months, 3 insiders have filed transactions with the SEC. ATXS insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Astria Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
ATXS insider trading · 5 questionsThe insiders of Astria Therapeutics, Inc. (ATXS) include executives and directors such as Violin Jonathan (Director), Milne Jill C. (CEO and President · Director), Komjathy Andrew (Chief Commercial Officer), among others. Over the past 12 months, 3 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026